

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Qyuns Therapeutics Co., Ltd.
江蘇荃信生物醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2509)

**(1) POLL RESULTS OF THE ANNUAL GENERAL MEETING
HELD ON MAY 29, 2026; AND
(2) DISSOLUTION OF THE SUPERVISORY COMMITTEE AND
RESIGNATION OF SUPERVISORS**

According to the notice (the “**Notice**”) and the circular (the “**Circular**”) dated May 8, 2026 of annual general meeting (the “**AGM**”) of Qyuns Therapeutics Co., Ltd. (the “**Company**”), the AGM of the Company was held at North Conference Room, 2nd Floor, Building 1, No. 907 Yaocheng Avenue, Taizhou City, Jiangsu Province, the PRC on Friday, May 29, 2026 at 10:00 a.m. Unless otherwise defined, capitalised terms in this announcement shall have the same meaning as given to them in the Circular.

The total number of the issued Shares of the Company as at the date of the AGM was 227,071,600 H Shares of which 2,708,200 H Shares were held by the Company as Treasury Shares. The above 2,708,200 H Shares held as Treasury Shares shall not be counted toward the number of Shares of the Company entitling holders to attend and vote on each of the resolutions proposed at the AGM, and no voting rights have been exercised in respect of such Shares. Accordingly, the total number of Shares entitling the holders to attend and vote for or against any of the proposed resolutions at the AGM was 224,363,400 Shares.

There were no Shares entitling the shareholders to attend and abstain from voting in favour of any of the proposed resolutions at the AGM as set out in Rule 13.40 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) (the “**Listing Rules**”). None of the shareholders of the Company has stated his or her intention in the Circular to vote against or abstain from voting on any resolutions at the AGM. There were no shareholders of the Company that were required under the Listing Rules to abstain from voting on any of the proposed resolutions at the AGM.

The number of shareholders and proxies of shareholders attending the AGM in person was 3. Shareholders and proxies of shareholders who attended the AGM held a total of 157,698,600 Shares with voting rights, representing approximately 70.29% of the total number of Shares with voting rights.

The holding of the AGM was in compliance with the requirements of the Company Law of the PRC (《中華人民共和國公司法》) and the Articles of Association of the Company.

Tricor Investor Services Limited, the Company's H share registrar, acted as the scrutineer for the vote-taking at the AGM.

The following Directors of the Company attended the AGM: Mr. Qiu Jiwan, Mr. Wu Yiliang and Mr. Lin Weidong as executive Directors; Mr. Yu Xi and Mr. Wu Zhiqiang as non-executive Directors; and Mr. Fung Che Wai, Anthony, Dr. Zou Zhongmei and Dr. Ling Jianqun as independent non-executive Directors.

VOTING RESULTS OF THE AGM

At the AGM of the Company held on May 29, 2026, all the proposed resolutions as set out in the Notice were taken by poll. The poll results are as follows:

Ordinary Resolutions		Number of Votes (%)		
		For	Against	Abstain
1.	To consider and approve the report of the Board of Directors of the Company for the year ended December 31, 2025.	157,698,600 (100%)	0 (0%)	0 (0%)
2.	To consider and approve the report of the Board of Supervisors of the Company for the year ended December 31, 2025.	157,698,600 (100%)	0 (0%)	0 (0%)
3.	To consider and approve the annual report of the Group which include the audited consolidated financial statements and the reports of the auditor of the Company for the year ended December 31, 2025.	157,698,600 (100%)	0 (0%)	0 (0%)
4.	To consider and approve the proposed profit distribution plan of the Company for the year ended December 31, 2025.	157,698,600 (100%)	0 (0%)	0 (0%)
5.	To consider and approve the 2026 remuneration scheme of Directors and Supervisors of the Company.	157,698,600 (100%)	0 (0%)	0 (0%)
6.	To consider and approve the engagement of KPMG as the auditor of the Company to hold office until the conclusion of the next annual general meeting of the Company and to authorize the Board to determine their remuneration.	157,698,600 (100%)	0 (0%)	0 (0%)
7.	To consider and approve the proposed change in use of proceeds from the Global Offering.	157,698,600 (100%)	0 (0%)	0 (0%)
As more than half of the votes were cast in favour of each of the resolutions numbered 1 to 7, all resolutions were duly passed as ordinary resolutions.				

Special Resolutions		Number of Votes (%)		
		For	Against	Abstain
8.	To consider and approve the proposed granting of the general mandates to the Board to issue Shares.	157,688,400 (99.99%)	10,200 (0.01%)	0 (0%)
9.	To consider and approve the proposed granting of the general mandates to the Board to repurchase H shares.	157,698,600 (100%)	0 (0%)	0 (0%)
10.	To consider and approve the dissolution of the Supervisory Committee and the proposed amendments to the Articles of Association, the Rules of Procedures for the General Meeting of Shareholders and the Rules of Procedures for the Board of Directors and authorize the Board to deal with on behalf of the Company all relevant procedures and matters to effect the amendments.	157,698,600 (100%)	0 (0%)	0 (0%)
11.	To consider and approve the proposed adoption of the 2026 Share Incentive Scheme.	157,688,400 (99.99%)	10,200 (0.01%)	0 (0%)
12.	Conditional upon the above special resolution No.11 being duly passed, to consider and approve the Scheme Mandate Limit.	157,688,400 (99.99%)	10,200 (0.01%)	0 (0%)
13.	Conditional upon the above special resolutions No.11 and No.12 being duly passed, to consider and approve the Service Provider Sublimit.	157,688,400 (99.99%)	10,200 (0.01%)	0 (0%)
As more than two-thirds of the votes were cast in favour of each of the resolutions numbered 8 to 13, all resolutions were duly passed as special resolutions.				

DISSOLUTION OF THE SUPERVISORY COMMITTEE AND RESIGNATION OF SUPERVISORS

The Board announces that, according to The Company Law of the People's Republic of China (《中華人民共和國公司法》) coming in force on July 1, 2024 (the “**PRC Company Law**”), a joint stock limited company may, in accordance with its articles of association, instead of having set up a supervisory committee, establish an audit committee which comprises directors of the board of directors and exercises the functions of the supervisory committee. As set out in the Circular, the proposed amendments to the Articles of Association included, among other things, the removal of the requirement of establishing a supervisory committee. Hence, following the approval by the Shareholders at the AGM in respect of the amendments of the Articles of Association, the Supervisory Committee has been dissolved accordingly with effect from May 29, 2026. Each of the Supervisors resigns as Supervisor with effect from May 29, 2026. Each of the Supervisors has confirmed that he or she has no disagreement with the Supervisory Committee and there is no matter relating to his or her resignation as a Supervisor that needs to be brought to the attention of the Shareholders or the Stock Exchange.

The Board would like to express heartfelt gratitude to each of the Supervisors for their valuable contributions and services to the Company during their tenures as Supervisors.

By Order of the Board
Qyuns Therapeutics Co., Ltd.
Mr. Qiu Jiwan

Chairman of the Board and Executive Director

Hong Kong, May 29, 2026

As at the date of this announcement, the Board comprises Mr. Qiu Jiwan as chairman and executive director, Mr. Wu Yiliang and Mr. Lin Weidong as executive directors, Mr. Yu Xi and Mr. Wu Zhiqiang as non-executive directors, and Mr. Fung Che Wai, Anthony, Dr. Zou Zhongmei and Dr. Ling Jianqun as independent non-executive directors.